Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
INOVIO PHARMACEUTICALS, INC. entered into Underwriting Agreement with Oppenheimer & Co. Inc. and Citizens JMP Securities, LLC, as representatives of the several underwriters named therein valued at approximately $33.2 million (effective 2024-04-15).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Oppenheimer & Co. Inc. and Citizens JMP Securities, LLC, as representatives of the several underwriters named therein
- Value
- approximately $33.2 million
- Effective
- 2024-04-15
Exact text from the filing
On April 15, 2024, Inovio Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Oppenheimer & Co. Inc. and Citizens JMP Securities, LLC, as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), relating to the issuance and sale by the Company in an underwritten registered direct offering (the “ Offering ”) of 2,536,258 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a price of $7.693 per share and pre-funded warrants to purchase up to 2,135,477 shares of Common Stock (the “ Pre-Funded Warrants ”) at a price of $7.692 per Pre-Funded Warrant, which represents the per share price for the Shares less the $0.001 per share exercise price for each Pre-Funded Warrant.
View on SEC.gov